pipette
ESEspañol

Timing the Target: Exploring the Circadian Transcriptome of Biologic Therapies in Asthma.

A. Akenroye, V. J. Carey, F. A. J. L. Scheer, S. T. Weiss

Preprint

In the authors' words

Background: Many of the immune pathways involved in asthma or in asthma treatment show circadian or diurnal variation. Understanding this variation can aid in biomarker discovery and/or therapy optimization. Objective: To evaluate if receptors, cytokines, and their pathways (n=46) targeted by currently approved biologics show significant diurnal rhythmicity and to identify their peak expression time. Methods: We used longitudinal bulk RNA sequencing datasets (discovery/replication cohorts: GSE113883 and GSE223613) and one microarray file (GSE39445) for cross-platform replication/validation. First, we used 16 canonical clock genes (including CLOCK, BMAL1, REV-ERB-beta) as positive controls to explore rhythmicity in each cohort. Thereafter, we evaluated if any targets of currently approved biologics or their corresponding receptors showed significant diurnal variation. For significant genes (Benjamini-Hochberg FDR<0.05), we estimated the baseline average, phase, peak-time of expression across the 24-hour day using clock time and quantified the cross-cohort consistency in the peak time of expression across the cohorts. Results: These cohorts included 453 longitudinal samples collected every two to four hours over a 24-28h cycle. Twelve (75%) of 16 evaluable clock genes showed significant rhythmicity. Only 34 of 46 (74%) asthma-related genes were evaluable across two or more cohorts. Of these 34 genes, 23 (68%) showed significant variation. Across all cohorts, the most preserved rhythmically expressed targets included many pathways or targets of monoclonal antibodies that are currently approved or in development: GATA3 and STAT6, master regulators of type 2 inflammation and IL4/IL13 signaling; chemokines, including the neutrophil chemoattractant, CXCL8; IL-5RA, benralizumab's target; FcRE1, suppressed by omalizumab; and IL1RL1(ST2) in clinical trials. Conclusion: Many therapeutic targets in asthma show significant diurnal rhythmicity. Future studies on how dosing time affects their therapeutic effectiveness while minimizing side effects are needed.

Main resultLimitation the authors admit

Appeared: Thursday, November 19. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.16.26368198